Fermi Inc. Suffers Sharp Decline Amid Neugebauer Exit
Fermi (FRMI) slid 2.72 % during the 24‑hour trading window that closed at 10:33 AM Central Europe on Friday, 23 October 2026. At a price of US $2.65 per share, the Dallas‑based real‑estate investment trust is now trading far below its 200‑day simple moving average of US $6.70 and well beneath the 52‑week high of US $30.90 set on 28 October 2025. The recent low of US $2.80 reached just a week earlier, on 21 October 2026, underscoring the rapid erosion of investor confidence.
Market Context
- Current market capitalisation: US $1.80 billion
- Shares outstanding: 639.9 million
- 24‑hour volume: US $46.5 million
- Last month’s performance: -44.36 %
With the last month’s decline eclipsing the average 200‑day trend, Fermi’s trajectory is alarmingly steep. The market’s appetite for Fermi has effectively disappeared, as evidenced by the negligible trading volume relative to its share count.
Neugebauer Family Exit
A Securities and Exchange Commission filing dated 22 October 2026 revealed that the Neugebauer family—specifically Toby R. Neugebauer and the Melissa A. Neugebauer 2020 Trust—sold a significant block of common shares. The transaction was executed at a weighted‑average price ranging from US $3.00 to US $3.195 per share, drastically reducing the family’s direct stake. While the trust and affiliated entities retain indirect ownership through related vehicles, the scale of the divestiture signals a profound loss of confidence from a key shareholder group.
This move is not merely a passive divestiture; it is a public admission that the current business model, asset portfolio, and governance structure no longer meet the family’s expectations of value creation. The fact that no other material events were reported in the filing only highlights that the Neugebauer exit is the sole catalyst behind the current slide.
Comparative Performance
For context, the 24‑hour performance of peer stocks is as follows:
| Stock | Ticker | % Change | Current Price (USD) | Market Cap (USD bn) | P/E Ratio |
|---|---|---|---|---|---|
| Merchants | MBIN | +2.71 % | 49.06 | 2.2 | 9.6 |
| Progyny | PGNY | -0.49 % | 29.12 | 2.2 | 30.91 |
| Stagwell | STGW | -0.22 % | 8.99 | 2.2 | 150.62 |
| Alamar Biosciences | ALMR | +11.68 % | 29.72 | 2.2 | — |
| Neogenomics | NEO | -3.81 % | 16.39 | 2.2 | — |
While Fermi’s peers are either stable or even enjoying modest gains, Fermi’s sharp decline stands out starkly. The contrast is not merely a statistical anomaly; it reflects the market’s perception that Fermi’s operational strategy is fundamentally flawed.
Critical Assessment
Ownership Concentration and Exit Strategy The Neugebauer family’s withdrawal of a sizeable block of shares indicates that major stakeholders are no longer willing to support the current trajectory. A real‑estate investment trust thrives on long‑term capital preservation; the exit of seasoned investors erodes both liquidity and credibility.
Valuation Disparity Trading at US $2.65 against a 200‑day SMA of US $6.70 demonstrates a valuation gap that is unsustainable. Even with the recent 52‑week low at US $2.80, the market refuses to acknowledge any upside, implying that future earnings potential is viewed as negligible.
Liquidity Concerns With US $46.5 million traded in the last 24 hours, the liquidity ratio is alarmingly low. This hampers the ability of new investors to enter the market, creating a vicious cycle of declining prices and shrinking investor base.
Governance Transparency The filing’s silence on any other material events may be interpreted as a lack of proactive governance. In an era where transparency is a prerequisite for market trust, the absence of substantive corporate communication further weakens Fermi’s position.
Peer Benchmarking Competitors such as Merchants (MBIN) and Alamar Biosciences (ALMR) are either gaining traction or at least maintaining stability. Fermi’s inability to match even modest peer performance signals operational inefficiencies and strategic misalignments.
Outlook
Unless Fermi undertakes a decisive restructuring—potentially including a fresh capital injection, a shift in asset strategy, or a comprehensive governance overhaul—the downward spiral is likely to continue. The Neugebauer family’s exit should serve as a wake‑up call for the board and remaining shareholders: complacency is no longer an option.
The market’s verdict is clear: Fermi’s current trajectory is unsustainable, and the only path forward is to confront the hard realities of its business model, re‑engage critical stakeholders, and rebuild the trust that has been eroded. Failure to do so will cement Fermi’s decline as a cautionary tale in corporate governance and investor relations.
